House Speaker
Pelosi’s plan, a targeted Medicare negotiation bill taking aim at drugs that have been on the market without competition, is slated to go through two key health committees in the House after it’s introduced. It’s also expected to be designated H.R. 3, a symbolic gesture noting it as part of the major bills making up Democrats’ domestic policy agenda.
However, progressives in the House are already grumbling that the proposal doesn’t go ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.